ProQR Therapeutics Past Earnings Performance
Past criteria checks 0/6
ProQR Therapeutics has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 51.2% per year.
Key information
9.9%
Earnings growth rate
23.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 51.2% |
Return on equity | -95.8% |
Net Margin | -130.2% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding
Dec 14There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01Revenue & Expenses Breakdown
How ProQR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 18 | -24 | 14 | 33 |
30 Jun 24 | 16 | -22 | 15 | 30 |
31 Mar 24 | 11 | -27 | 16 | 28 |
31 Dec 23 | 7 | -28 | 16 | 25 |
30 Sep 23 | 5 | -36 | 14 | 28 |
30 Jun 23 | 4 | -54 | 17 | 38 |
31 Mar 23 | 4 | -59 | 18 | 44 |
31 Dec 22 | 4 | -64 | 19 | 51 |
30 Sep 22 | 4 | -69 | 21 | 53 |
30 Jun 22 | 4 | -61 | 20 | 48 |
31 Mar 22 | 3 | -63 | 19 | 47 |
31 Dec 21 | 2 | -61 | 17 | 42 |
30 Sep 21 | 2 | -57 | 16 | 38 |
30 Jun 21 | 2 | -55 | 14 | 35 |
31 Mar 21 | 1 | -43 | 13 | 34 |
31 Dec 20 | 1 | -47 | 14 | 38 |
30 Sep 20 | 1 | -52 | 14 | 44 |
30 Jun 20 | 1 | -51 | 14 | 46 |
31 Mar 20 | 2 | -58 | 14 | 47 |
31 Dec 19 | 2 | -56 | 13 | 46 |
30 Sep 19 | 3 | -51 | 14 | 42 |
30 Jun 19 | 5 | -45 | 13 | 37 |
31 Mar 19 | 6 | -40 | 13 | 34 |
31 Dec 18 | 6 | -37 | 13 | 30 |
30 Sep 18 | 4 | -35 | 11 | 28 |
30 Jun 18 | 2 | -40 | 11 | 29 |
31 Mar 18 | 1 | -44 | 11 | 31 |
31 Dec 17 | 1 | -44 | 11 | 31 |
30 Sep 17 | 1 | -41 | 10 | 31 |
30 Jun 17 | 1 | -41 | 9 | 32 |
31 Mar 17 | 1 | -39 | 9 | 33 |
31 Dec 16 | 2 | -39 | 9 | 32 |
30 Sep 16 | 3 | -36 | 9 | 30 |
30 Jun 16 | 3 | -33 | 9 | 28 |
31 Mar 16 | 3 | -31 | 8 | 25 |
31 Dec 15 | 3 | -21 | 7 | 23 |
30 Sep 15 | 3 | -17 | 7 | 20 |
30 Jun 15 | 1 | -14 | 8 | 17 |
31 Mar 15 | 1 | -10 | 8 | 14 |
31 Dec 14 | 0 | -12 | 7 | 10 |
30 Sep 14 | 0 | -12 | 5 | 8 |
30 Jun 14 | 0 | -9 | 3 | 6 |
31 Mar 14 | 0 | -5 | 1 | 4 |
31 Dec 13 | 0 | -3 | 1 | 3 |
Quality Earnings: PRQR is currently unprofitable.
Growing Profit Margin: PRQR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRQR is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PRQR has a negative Return on Equity (-95.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 00:49 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ProQR Therapeutics N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jonathan Aschoff | B. Riley Wealth |
Eliana Merle | Cantor Fitzgerald & Co. |
Steven Seedhouse | CGS International |